A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia
NCT ID: NCT00599638
Last Updated: 2021-08-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
72 participants
INTERVENTIONAL
2008-04-09
2008-12-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
NCT00394901
Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia
NCT01270828
To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.
NCT00150436
A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia
NCT00629681
Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia
NCT03809702
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
pregabalin
75mg bid titrating to 150mg bid on day 4
2
pregabalin/PF-00489791
Pregabalin 75mg bid titrating to 150mg bid on day 4; PF-00489791: 4mg od titrating to 10mg od on day 4
3
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pregabalin
75mg bid titrating to 150mg bid on day 4
pregabalin/PF-00489791
Pregabalin 75mg bid titrating to 150mg bid on day 4; PF-00489791: 4mg od titrating to 10mg od on day 4
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pain present for more than 3 months after healing of herpes zoster skin rash
* VAS score of \>=40mm at screening and baseline visits
Exclusion Criteria
* Skin conditions in the affected dermatome that could alter sensation other than postherpetic neuralgia
* History or diagnosis of DSM IV major depressive disorder
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
North Alabama RadioPharmacy
Huntsville, Alabama, United States
Tennessee Valley Pain Consultants
Huntsville, Alabama, United States
River Region Research, LLC
Tallassee, Alabama, United States
Radiant Research
Chandler, Arizona, United States
Novara Clinical Research
Mesa, Arizona, United States
Community Medical Providers
Clovis, California, United States
Sierra Medical Research (Administrative only site)
Fresno, California, United States
Prime-Care Clinical Research
Mission Viejo, California, United States
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida, United States
Bradenton Research Center
Bradenton, Florida, United States
Arthritis Associates of South Florida
Delray Beach, Florida, United States
Delray Research Associates
Delray Beach, Florida, United States
Office of Laszlo J Mate, M.D.
West Palm Beach, Florida, United States
American Medical Research, Inc.
Oak Brook, Illinois, United States
Beacon Clinical Research
Brockton, Massachusetts, United States
ICPS Group
Norwood, Massachusetts, United States
Neurological Research Center at Hattiesburg Clinic
Hattiesburg, Mississippi, United States
CRC of Jackson
Jackson, Mississippi, United States
Physician's Surgery Center
Jackson, Mississippi, United States
Clinvest
Springfield, Missouri, United States
Centennial Park Medical Building
North Platte, Nebraska, United States
Neurology Associates of Great Plains
North Platte, Nebraska, United States
Finger Lakes Clinical Research
Rochester, New York, United States
North State Clinical Research, PLLC
Lenoir, North Carolina, United States
The Center for Clinical Research
Winston-Salem, North Carolina, United States
Legacy Pharma Research
Bismarck, North Dakota, United States
Patient Priority Clinical Sites, LLC
Cincinnati, Ohio, United States
Lynn Health Science Institute
Oklahoma City, Oklahoma, United States
Mark A. Fisher, MD-Private Practice
Oklahoma City, Oklahoma, United States
Absolute Primary Care, P.C.
Cranberry Twp., Pennsylvania, United States
John P. Murtha Neuroscience and Pain Institute
Johnstown, Pennsylvania, United States
Memorial Medical Center
Johnstown, Pennsylvania, United States
New England Center for Clinical Research
Cranston, Rhode Island, United States
Medical Clinic of North Texas
Arlington, Texas, United States
FutureSearch Trials of Neurology
Austin, Texas, United States
Futuresearch Trials
Austin, Texas, United States
Pinnacle Pain Medicine
Dallas, Texas, United States
The Medical Group Of Texas
Fort Worth, Texas, United States
Medical and Surgical Clinic of Irving
Irving, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B0261002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.